Results 51 to 60 of about 1,008 (88)

Radioligand therapy for primary brain tumors: a PRISMA-based systematic review of meningiomas and gliomas. [PDF]

Front Med (Lausanne)
Grassi I, Sansovini M, Matteucci F, Marini I, Caroli P, Celli M, Fantini L, Rossetti V, Gurrieri L, Riva N, Rossi A, Bronico I, Iorio VD, Sarnelli A, Arpa D, Nicolini S.   +15 more
europepmc   +1 more source

First Real-World Evidence on the Safety and Effectiveness of Lutathera^TM for Treating Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Insights from Post-Marketing Surveillance. [PDF]

Cancers (Basel)
Kim YI, Suh HY, Kang Y, Cho H, Hyun SH, Song YS, Ha S, Kang KW.   +7 more
europepmc   +1 more source

A Theranostic Study of ¹⁷⁷Lu-Labeled Anti-ADAM9 Antibody for the Treatment of Triple-Negative Breast Cancer. [PDF]

Bioconjug Chem
Zhang H, Tang M, Hao X, Lin B, Du H, Long H, Hu J, Luo R, Wu W, Du X.   +9 more
europepmc   +1 more source

Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer. [PDF]

Mol Pharm
Taş H, Schäfer M, Shuja-Uddin A, Bauder-Wüst U, Kovacs Dos Santos L, Bartnitzky L, Oden F, Platzk M, König T, Rüther PL, Pook E, Dvořáková Bendová K, Nový Z, Petřík M, Hagemann UB, Benešová-Schäfer M.   +15 more
europepmc   +1 more source

Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [¹⁷⁷Lu]Lu-DOTA-MGS5 in Patients with Small Cell Lung Cancer. [PDF]

Pharmaceutics
Zavvar TS, Santo G, Gruber L, Kronthaler A, Hagenbuchner J, Skvortsova I, Piro I, Steiger K, Martinovic V, Minasch D, Löffler-Ragg J, di Santo G, Virgolini IJ, von Guggenberg E.   +13 more
europepmc   +1 more source

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals. [PDF]

EJNMMI Radiopharm Chem
Ntihabose CM, Handula M, Piet A, Beekman S, van Dalen L, Eskandari N, Aydogan A, Stuurman D, de Ridder C, Konijnenberg M, Seimbille Y, de Blois E.   +11 more
europepmc   +1 more source

Radioligand Therapy in Cancer Management: A Global Perspective. [PDF]

Cancers (Basel)
Ninatti G, Lee ST, Scott AM.
europepmc   +1 more source

Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging. [PDF]

EJNMMI Radiopharm Chem
Obeid K, Bezverkhniaia E, Tolmachev V, Orlova A, Kanellopoulos P.   +4 more
europepmc   +1 more source

The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion. [PDF]

Adv Ther
Tafuto S, Lastoria S, Panzuto F, Antonuzzo L, Campana D, Cingarlini S, Cives M, Ferone D, Filice A, Giuffrida D, Maccauro M, Partelli S, Fazio N.   +12 more
europepmc   +1 more source

The novel [⁶⁸Ga]Ga-DOTA-C6-anti-integrin peptide in glioblastoma. [PDF]

RSC Adv
Carron J, Melo GF, da Silva FFA, Alves FL, Santos MEOA, Rodrigues VPC, Ali A, Franchi GC, de Carvalho JE, Ruiz ALTG, Fuscaldi LL, Malavolta L, Lima CSP.   +12 more
europepmc   +1 more source